Drug Profile
CAL 02
Alternative Names: CAL-02Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Combioxin
- Developer Eagle Pharmaceuticals; LASCCO
- Class Antibacterials
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Community-acquired pneumonia
Most Recent Events
- 07 Sep 2023 Phase-II clinical trials in Community-acquired pneumonia (Adjunctive treatment) in Argentina, Brazil (IV) (NCT05776004)
- 01 Jul 2023 Phase-II clinical trials in Community-acquired pneumonia (Adjunctive treatment) in Georgia, South Africa (IV) (NCT05776004)
- 14 Jun 2023 Eagle Pharmaceuticals has patent protection for CAL 02 in Europe and Japan